AZX 1101

Drug Profile

AZX 1101

Alternative Names: AZX1101

Latest Information Update: 06 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AzurRx BioPharma
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Nosocomial infections

Most Recent Events

  • 01 Dec 2016 Preclinical trials in Nosocomial infections (Prevention) in France (PO)
  • 01 Dec 2016 AzurRx Biopharma announces intention to submit IND application in 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top